CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies

Molecular Psychiatry

Volumn 21, Issue 4, 2016, Pages 574-584

  Gray, L R ^a,b   Cowley, D ^c   Welsh, C ^a   Lu, H K ^a,d   Brew, B J ^e   Lewin, S R ^a,d,f   Wesselingh, S L ^a,g   Gorry, P R ^a,b,h   Churchill, M J ^a,b  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f ALFRED HOSPITAL   (Australia)

^g SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^h RMIT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; DISULFIRAM; HISTONE DEACETYLASE INHIBITOR; LATENCY REVERSING AGENT; PANOBINOSTAT; ROMIDEPSIN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VORINOSTAT; DEPSIPEPTIDE; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ARTICLE; BINDING AFFINITY; COHORT ANALYSIS; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; ADULT; BRAIN; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; HIV INFECTIONS; JURKAT CELL LINE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TRANSCRIPTION INITIATION; VIROLOGY; VIRUS LATENCY;

ADULT; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; COHORT STUDIES; DEPSIPEPTIDES; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; HYDROXAMIC ACIDS; INDOLES; JURKAT CELLS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TERMINAL REPEAT SEQUENCES; TRANSCRIPTIONAL ACTIVATION; VIRUS LATENCY;

EID: 84940099508     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.111     Document Type: Article

References (71)

1. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIVinfected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 2014; 1: e12-e21.
2. Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 2014; 58: 883-890.
3. Choudhary SK, Archin NM, Margolis DM. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+). T cells. J Infect Dis 2008; 197: 1162-1170.
4. Li Z, Guo J, Wu Y, Zhou Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res 2013; 41: 277-287.
5. Bernhard W, Barreto K, Saunders A, Dahabieh MS, Johnson P, Sadowski I. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett 2011; 585: 3549-3554.
6. Churchill M, Nath A. Where does HIV hide? A focus on the central nervous system. Curr Opinion HIV AIDS 2013; 8: 165-169.
7. Gray L, Roche M, Churchill MJ, Sterjovski J, Ellett A, Poumbourios P, et al. Tissuespecific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J Virol 2009; 83: 5430-5441.
8. Korber BT, Kunstman KJ, Patterson BK, Furtado M, McEvilly MM, Levy R, et al. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol 1994; 68: 7467-7481.
9. Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, et al. Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol 2003; 77: 12336-12345.
10. Thomas ER, Dunfee RL, Stanton J, Bogdan D, Kunstman K, Wolinsky SM, et al. High frequency of defective vpu compared with tat and rev genes in brain from patients with HIV type 1-Associated dementia. AIDS Res Hum Retroviruses 2007; 23: 575-580.
11. Thomas ER, Dunfee RL, Stanton J, Bogdan D, Taylor J, Kunstman K, et al. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology 2007; 360: 105-119.
12. Tornatore C, Nath A, Amemiya K, Major EO. Persistent human immunodeficiency virus type 1 infection in human fetal glial cells reactivated by T-cell factor(s). or by the cytokines tumor necrosis factor alpha and interleukin-1 beta. J Virol 1991; 65: 6094-6100.
13. Watkins BA, Dorn HH, Kelly WB, Armstrong RC, Potts BJ, Michaels F, et al. Specific tropism of HIV-1 for microglial cells in primary human brain cultures. Science 1990; 249: 549-553.
14. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 1997; 71: 2059-2071.
15. Gray LR, Cowley D, Crespan E, Welsh C, Mackenzie C, Wesselingh SL, et al. Reduced basal transcriptional activity of central nervous system-derived HIV type 1 long terminal repeats. AIDS Res Hum Retroviruses 2013; 29: 365-370.
16. Rosen CA, Sodroski JG, Haseltine WA. The location of cis-Acting regulatory sequences in the human T cell lymphotropic virus type III. (HTLV-III/LAV). long terminal repeat. Cell 1985; 41: 813-823.
17. Siekevitz M, Josephs SF, Dukovich M, Peffer N, Wong-Staal F, Greene WC. Activation of the HIV-1 LTR by T cell mitogens and the trans-Activator protein of HTLV-I. Science 1987; 238: 1575-1578.
18. Brady T, Agosto LM, Malani N, Berry CC, O'Doherty U, Bushman F. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 2009; 23: 1461-1471.
19. Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J 2001; 20: 1726-1738.
20. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004; 2: E234.
21. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002; 110: 521-529.
22. He G, Margolis DM. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1. (HIV-1). by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Bioly 2002; 22: 2965-2973.
23. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virology 2007; 81: 10914-10923.
24. Li Y, Mak G, Franza BR Jr. In vitro study of functional involvement of Sp1, NF-kappa B/Rel, and AP1 in phorbol 12-myristate 13-Acetate-mediated HIV-1 long terminal repeat activation. J Biol Chem 1994; 269: 30616-30619.
25. Margolis DM, Somasundaran M, Green MR. Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J Virol 1994; 68: 905-910.
26. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25: 139-149.
27. Kaehlcke K, Dorr A, Hetzer-Egger C, Kiermer V, Henklein P, Schnoelzer M, et al. Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation. Mol Cell 2003; 12: 167-176.
28. Mahmoudi T, Parra M, Vries RG, Kauder SE, Verrijzer CP, Ott M, et al. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Biol Chem 2006; 281: 19960-19968.
29. Marzio G, Tyagi M, Gutierrez MI, Giacca M. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc Natl Acad Sci USA 1998; 95: 13519-13524.
30. Steger DJ, Eberharter A, John S, Grant PA, Workman JL. Purified histone acetyltransferase complexes stimulate HIV-1 transcription from preassembled nucleosomal arrays. Proc Natl Acad Sci USA 1998; 95: 12924-12929.
31. Burnett JC, Miller-Jensen K, Shah PS, Arkin AP, Schaffer DV. Control of stochastic gene expression by host factors at the HIV promoter. PLoS Pathog 2009; 5: e1000260.
32. Ait-Khaled M, McLaughlin JE, Johnson MA, Emery VC. Distinct HIV-1 long terminal repeat quasispecies present in nervous tissues compared to that in lung, blood and lymphoid tissues of an AIDS patient. AIDS 1995; 9: 675-683.
33. Buzy JM, Lindstrom LM, Zink MC, Clements JE. HIV-1 in the developing CNS: developmental differences in gene expression. Virology 1995; 210: 361-371.
34. Canonne-Hergaux F, Aunis D, Schaeffer E. Interactions of the transcription factor AP-1 with the long terminal repeat of different human immunodeficiency virus type 1 strains in Jurkat, glial, and neuronal cells. J Virol 1995; 69: 6634-6642.
35. Corboy JR, Buzy JM, Zink MC, Clements JE. Expression directed from HIV long terminal repeats in the central nervous system of transgenic mice. Science 1992; 258: 1804-1808.
36. Corboy JR, Garl PJ. HIV-1 LTR DNA sequence variation in brain-derived isolates. J Neurovirol 1997; 3: 331-341.
37. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 1987; 236: 819-822.
38. Kurth J, Buzy JM, Lindstrom L, Clements JE. In vivo transcriptional regulation of the human immunodeficiency virus in the central nervous system in transgenic mice. J Virol 1996; 70: 7686-7694.
39. Zeichner SL, Hirka G, Andrews PW, Alwine JC. Differentiation-dependent human immunodeficiency virus long terminal repeat regulatory elements active in human teratocarcinoma cells. J Virol 1992; 66: 2268-2273.
40. Harrich D, Garcia J, Wu F, Mitsuyasu R, Gonazalez J, Gaynor R. Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat. J Virol 1989; 63: 2585-2591.
41. Ross EK, Buckler-White AJ, Rabson AB, Englund G, Martin MA. Contribution of NFkappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. J Virol 1991; 65: 4350-4358.
42. Sune C, Garcia-Blanco MA. Sp1 transcription factor is required for in vitro basal and Tat-Activated transcription from the human immunodeficiency virus type 1 long terminal repeat. J Virol 1995; 69: 6572-6576.
43. Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, Birch CJ, et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol 2001; 75: 10073-10089.
44. Major EO, Miller AE, Mourrain P, Traub RG, De Widt E, Sever J. Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci USA 1985; 82: 1257-1261.
45. Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 1977; 19: 621-626.
46. Churchill MJ, Ramsay RG, Rhodes DI, Deacon NJ. c-Myb influences HIV type 1 gene expression and virus production. AIDS Res Hum Retroviruses 2001; 17: 1481-1488.
47. Churchill MJ, Gorry PR, Cowley D, Lal L, Sonza S, Purcell DF, et al. Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol 2006; 12: 146-152.
48. Smit TK, Wang B, Ng T, Osborne R, Brew B, Saksena NK. Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without AIDS dementia complex. (ADC): evidence for neurotropic HIV variants. Virology 2001; 279: 509-526.
49. Thompson KA, Churchill MJ, Gorry PR, Sterjovski J, Oelrichs RB, Wesselingh SL, et al. Astrocyte specific viral strains in HIV dementia. Ann Neurol 2004; 56: 873-877.
50. Shah S, Alexaki A, Pirrone V, Dahiya S, Nonnemacher MR, Wigdahl B. Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT/enhancer binding protein site I. Virol J 2014; 11: 92.
51. Jones KA, Kadonaga JT, Luciw PA, Tjian R. Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science 1986; 232: 755-759.
52. McAllister JJ, Phillips D, Millhouse S, Conner J, Hogan T, Ross HL, et al. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication. Virology 2000; 274: 262-277.
53. Kilareski EM, Shah S, Nonnemacher MR, Wigdahl B. Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology 2009; 6: 118.
54. Chiang CM, Roeder RG. Cloning of an intrinsic human TFIID subunit that interacts with multiple transcriptional activators. Science 1995; 267: 531-536.
55. Emili A, Greenblatt J, Ingles CJ. Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein. Mol Cell Biol 1994; 14: 1582-1593.
56. Yedavalli VS, Benkirane M, Jeang KT. Tat and trans-Activation-responsive. (TAR). RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J Biol Chem 2003; 278: 6404-6410.
57. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, et al. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 1999; 19: 5504-5511.
58. Widlak P, Gaynor RB, Garrard WT. In vitro chromatin assembly of the HIV-1 promoter. ATP-dependent polar repositioning of nucleosomes by Sp1 and NF kappaB. J Biol Chem 1997; 272: 17654-17661.
59. Marban C, Suzanne S, Dequiedt F, De Walque S, Redel L, Van Lint C, et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 2007; 26: 412-423.
60. Leid M, Ishmael JE, Avram D, Shepherd D, Fraulob V, Dolle P. CTIP1 and CTIP2 are differentially expressed during mouse embryogenesis. Gene Expr Patterns 2004; 4: 733-739.
61. Arlotta P, Molyneaux BJ, Chen J, Inoue J, Kominami R, Macklis JD. Neuronal subtype-specific genes that control corticospinal motor neuron development in vivo. Neuron 2005; 45: 207-221.
62. Marban C, Redel L, Suzanne S, Van Lint C, Lecestre D, Chasserot-Golaz S, et al. COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells. Nucleic Acids Res 2005; 33: 2318-2331.
63. du Chene I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C, et al. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J 2007; 26: 424-435.
64. Marsili G, Remoli AL, Sgarbanti M, Battistini A. Role of acetylases and deacetylase inhibitors in IRF-1-mediated HIV-1 long terminal repeat transcription. Ann N Y Acad Sci 2004; 1030: 636-643.
65. Brady J, Kashanchi F. Tat gets the "green" light on transcription initiation. Retrovirology 2005; 2: 69.
66. Stojanova A, Caro C, Jarjour RJ, Oster SK, Penn LZ, Germinario RJ. Repression of the human immunodeficiency virus type-1 long terminal repeat by the c-Myc oncoprotein. J Cell Biochem 2004; 92: 400-413.
67. Churchill MJ, Cowley DJ, Wesselingh SL, Gorry PR, Gray LR. HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research. J Neurovirol 2015; 21: 290-300.
68. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog 2014; 10: e1004473.
69. Søgaard OS, Graversen ME, Leth S, Brinkmann CR, Kjær A-S, Olesen R, et al. The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays. 20th International AIDS Conference. (AIDS 2014). 2014; 1, TUAA0106LB.
70. Deeks SG. HIV: shock and kill. Nature 2012; 487: 439-440.
71. International ASSWGoHIVC, Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12: 607-614.